WIESBADEN, Germany, May 25, 2022 / B3C newswire / -- The International Centers for Precision Oncology (ICPO) Foundation is pleased to announce new support from Petrichor Healthcare Capital Management (Petrichor) and the appointment of Tadd Wessel, Petrichor’s Founder and Managing Partner, to the ICPO Board of Curators.
Together with the Foundation´s established industry partners, Petrichor will support ICPO’s important mission to scale access of Molecularly Targeted Precision Oncology diagnostics and therapeutics for the benefit of cancer patients globally. The Foundation encourages all leaders from the pharmaceutical, medical, financial and philanthropic sectors to join its cause to set a new standard for treatment and build a global community of International Centers for Precision Oncology based upon our shared knowledge and experience.
Tadd Wessel is a leading healthcare investor with over 20 years of international strategic and financial healthcare experience. As a member of the ICPO Board of Curators, Tadd and the Petrichor team will use their industry centrality to facilitate necessary collaborations between all stakeholders to accelerate the development and adoption of precision oncology technologies.
“I look forward to helping further the ICPO Foundation´s important cause,” said Mr. Wessel. “Precision Oncology has demonstrated the potential to fundamentally improve cancer outcomes. Diagnosing cancer early, treating it precisely, and providing individualized care to large numbers of patients requires a tremendous collaborative global effort. I am grateful to the ICPO Foundation for its committed membership and humanitarian mission, and I look forward to using my role to have a positive impact for patients by increasing access to these innovative treatments”.
“We are delighted that Tadd has joined our Board of Curators”, commented Oliver Buck, Chairman of the ICPO Board of Curators. “His exceptional healthcare experience and vast network will tremendously aid our global mission and help cancer patients in need receive the best available individual treatment without regard to origin, country or social status.”
“We warmly welcome Tadd as a new ICPO Board of Curators Member and are proud to have his outstanding expertise now available to initiate joint projects with a higher purpose and achieve improvements with sustainability”, added Odile Jaume, CEO of the ICPO Foundation.
About Targeted Molecular Precision Oncology
Targeted Molecular Precision Oncology follows the multidisciplinary approach to diagnosis and treatment of cancer, whereas the cancer patient is considered as an individual who should be provided with targeted therapies, based on their unique biology and their disease. Precision Oncology utilizes molecular profiling of tumors to identify targetable alterations. The aim is to determine the most favorable therapy for an individual patient in order to improve quality of life as well as treatment results.
The International Centers for Precision Oncology Foundation (ICPO) is a German non-profit organization established in 2019 by leading medical and industry entrepreneurs. Recognizing a paradigm shift in cancer care from one size fits all to a personalized approach, the ICPO is helping build momentum to scale global patient access to Molecularly Targeted Precision Oncology to accommodate this shift. To scale patient access, ICPO aims to develop a network of International Centers for Precision Oncology organized in a Social Franchise model based on shared know-how, certified education, and design and process standardization enabling best clinical practice valid globally. Furthermore, the ICPO Foundation empowers its Centers network within a highly inclusive Community spearheading its model and living up to the Precision Oncology promise to be curative and abundant to all patients in need, irrespectively of region, country, or social status.
About Petrichor Healthcare Capital Management
Petrichor Healthcare Capital Management partners with world-class healthcare managers and businesses to provide customized investment structures and support. The Petrichor team has completed over 90 investments representing more than $5 billion in invested capital and has held over 30 board seats. Petrichor maintains a deep in-house understanding of healthcare products and services, including scientific, technical, and commercial expertise. This healthcare expertise, together with a breadth of experience investing across sectors, geographies, and capital structures, provides a unique combination to help build successful companies.
Community & Communication Officer
+ 49 611 341 486 30
Keywords: Humans; Fund Raising; Precision Medicine; Organizations, Nonprofit; Medical Oncology; Molecular Targeted Therapy; Neoplasms; Germany
Published by B3C newswire